A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
复制标题
一种多基因表达测定法，以预测乳房原位导管癌的局部复发风险。
DOI：
10.1093/jnci/djt067
复制
发表时间：
2013-05-15
期刊：
影响因子：
--
通讯作者：
Badve S
中科院分区：
文献类型：
--
作者：
Solin LJ;Gray R;Baehner FL;Butler SM;Hughes LL;Yoshizawa C;Cherbavaz DB;Shak S;Page DL;Sledge GW Jr;Davidson NE;Ingle JN;Perez EA;Wood WC;Sparano JA;Badve S
对于患有乳腺导管原位癌(DCIS)的女性，在没有放射治疗的情况下，手术切除后发生同侧乳腺事件(IBE；定义为DCIS的局部复发或浸润性癌)的风险并不是由临床和病理特征很好地定义的。在东部合作肿瘤学小组(ECOG)E5194研究中，对接受手术切除而不接受放射治疗的DCIS患者进行了Oncotype DX乳腺癌检测。使用COX回归分析前瞻性定义的DCIS评分(由7个癌症相关基因和5个参考基因计算)与发生IBE的风险之间的关系。所有的统计检验都是双面的。有327名患者有足够的组织进行分析。连续的DCIS评分与发生IBE的风险(危险比[HR]=2.31，95%可信区间[CI]=1.15至4.49；P=0.02)和侵袭性IBE(未调整的HR=3.68，95%CI=1.34至9.62；P=.01)显著相关。对于预先指定的低、中、高三个风险组，发生IBE的10年风险分别为10.6%、26.7%和25.9%，而发生侵袭性IBE的10年风险分别为3.7%、12.3%和19.2%(LOG等级均为P≤.006)。在多变量分析中，与IBE风险相关的因素是DCIS评分、肿瘤大小和绝经状态(均P≤.02)。DCIS评分量化了IBE风险和侵袭性IBE风险，补充了传统的临床和病理因素，并为符合ECOG E5194标准的DCIS女性提供了一种新的临床工具，以改进选择个性化治疗。
For women with ductal carcinoma in situ (DCIS) of the breast, the risk of developing an ipsilateral breast event (IBE; defined as local recurrence of DCIS or invasive carcinoma) after surgical excision without radiation is not well defined by clinical and pathologic characteristics. The Oncotype DX breast cancer assay was performed for patients with DCIS treated with surgical excision without radiation in the Eastern Cooperative Oncology Group (ECOG) E5194 study. The association of the prospectively defined DCIS Score (calculated from seven cancer-related genes and five reference genes) with the risk of developing an IBE was analyzed using Cox regression. All statistical tests were two-sided. There were 327 patients with adequate tissue for analysis. The continuous DCIS Score was statistically significantly associated with the risk of developing an IBE (hazard ratio [HR] = 2.31, 95% confidence interval [CI] = 1.15 to 4.49; P = .02) when adjusted for tamoxifen use (prespecified primary analysis) and with invasive IBE (unadjusted HR = 3.68, 95% CI = 1.34 to 9.62; P = .01). For the prespecified DCIS risk groups of low, intermediate, and high, the 10-year risks of developing an IBE were 10.6%, 26.7%, and 25.9%, respectively, and for an invasive IBE, 3.7%, 12.3%, and 19.2%, respectively (both log rank P ≤ .006). In multivariable analyses, factors associated with IBE risk were DCIS Score, tumor size, and menopausal status (all P ≤ .02). The DCIS Score quantifies IBE risk and invasive IBE risk, complements traditional clinical and pathologic factors, and provides a new clinical tool to improve selecting individualized treatment for women with DCIS who meet the ECOG E5194 criteria.
登录
查看更多内容
影响因子：
45.3
作者：
Kim, Chungyeul;Tang, Gong;Paik, Soonmyung
通讯作者：
Paik, Soonmyung
DOI：
10.1046/j.1524-4741.2001.99124.x
发表时间：
2001-09-01
期刊：
The breast journal
影响因子：
--
作者：
Miller, N A;Chapman, J A;Hanna, W M
通讯作者：
Hanna, W M
影响因子：
45.3
作者：
Bijker, Nina;Meijnen, Philip;Rutgers, Emiel J. Th.
通讯作者：
Rutgers, Emiel J. Th.
影响因子：
3.4
作者：
Drury, Suzanne;Salter, Janine;Dowsett, Mitch
通讯作者：
Dowsett, Mitch
影响因子：
8.8
作者：
Dodwell, D.;Clements, K.;Bishop, H.
通讯作者：
Bishop, H.